Derrick Meadow, APRN
Psychiatric/Mental Health · Cordova, TNNPI 1992338719
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 65.6% of it on its own, with 20 other manufacturers making up the rest. Among psychiatric/mental health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 499 payments — averaging $68.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$22K
- Alkermes, Inc.$6K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Vanda Pharmaceuticals Inc.$924
- Neurocrine Biosciences, Inc.$705
- plus $2K from 15 others
What the payments were for
- Consulting fees$3,0509%
- Speaking & faculty fees$19,42057%
- Travel & lodging$2,6378%
- Food & beverage$9,09327%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 89 | $22,455 |
| Alkermes, Inc. | 48 | $5,819 |
| AbbVie | 85 | $1,176 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $1,023 |
| Vanda Pharmaceuticals Inc. | 59 | $924 |
| Neurocrine Biosciences, Inc. | 40 | $705 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $380 |
| Indivior Inc. | 22 | $376 |
| Otsuka America Pharmaceutical, Inc. | 11 | $299 |
| E.r. Squibb & Sons, L.L.C. | 10 | $278 |
| Idorsia Pharmaceuticals US Inc | 20 | $230 |
| Sunovion Pharmaceuticals Inc. | 12 | $218 |
| Merck | 6 | $93 |
| Lundbeck LLC | 4 | $85 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Tris Pharma Inc | 2 | $33 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Noven Therapeutics, LLC | 2 | $27 |
| Johnson & Johnson | 1 | $23 |
| Eisai Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,246 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 26 | $221,909 |
| VraylarCariprazine Hcl | 141 | $205,178 |
| AristadaAripiprazole Lauroxil | 44 | $138,754 |
| Invega TrinzaPaliperidone Palmitate | 19 | $138,245 |
| UzedyRisperidone | 42 | $131,079 |
| FanaptIloperidone | 42 | $101,606 |
| Invega SustennaPaliperidone Palmitate | 36 | $98,235 |
| RexultiBrexpiprazole | 58 | $96,152 |
| BelsomraSuvorexant | 144 | $64,064 |
| LybalviOlanzapine/Samidorphan Malate | 29 | $46,778 |
| Chlorpromazine Hcl | 70 | $39,613 |
| Abilify MaintenaAripiprazole | 14 | $35,534 |
| Aripiprazole | 362 | $24,701 |
| TrintellixVortioxetine Hydrobromide | 33 | $19,800 |
| Lurasidone Hcl | 66 | $17,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $23 | $236,48055 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $705 | $221,90926 claims |
| AbbVieVraylar | $1,176 | $205,178141 claims |
| Alkermes, Inc.Aristada, Lybalvi | $5,819 | $185,53273 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $299 | $131,68572 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $22,455 | $131,07942 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $924 | $101,60642 claims |
| MerckBelsomra | $93 | $64,064144 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $380 | $24,01445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Cordova
- Uthappa MukatiraCordova$44K
- John RedmondCordova$23K
- Mark HesselrodeCordova$9K
- Amanda WoodallCordova$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
- Mary AllenMemphis$422K
- Lauren HansenNashville$263K
- Joshua ThompsonChattanooga$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.